Daniela Thommen: We are excited to share our new work in Cancer Discovery AACR Journals, in which we explore a CD8-targeted IL2 to revive dysfunctional T cells in anti-PD1 resistant human cancers

Daniela Thommen: We are excited to share our new work in Cancer Discovery AACR Journals, in which we explore a CD8-targeted IL2 to revive dysfunctional T cells in anti-PD1 resistant human cancers

Daniela Thommen: We are excited to share our new work in Cancer Discovery AACR Journals, in which we explore a CD8-targeted IL2 to revive dysfunctional T cells in anti-PD1 resistant human cancers

Daniela Thommen: We are excited to share our new work in Cancer Discovery AACR Journals, in which we explore a CD8-targeted IL2 to revive dysfunctional T cells in anti-PD1 resistant human cancers

Daniela Thommen: We are excited to share our new work in Cancer Discovery AACR Journals, in which we explore a CD8-targeted IL2 to revive dysfunctional T cells in anti-PD1 resistant human cancers

Daniela Thommen: We are excited to share our new work in Cancer Discovery AACR Journals, in which we explore a CD8-targeted IL2 to revive dysfunctional T cells in anti-PD1 resistant human cancers

Daniela Thommen: We are excited to share our new work in Cancer Discovery AACR Journals, in which we explore a CD8-targeted IL2 to revive dysfunctional T cells in anti-PD1 resistant human cancers

Daniela Thommen: We are excited to share our new work in Cancer Discovery AACR Journals, in which we explore a CD8-targeted IL2 to revive dysfunctional T cells in anti-PD1 resistant human cancers

T cells